Loftair Capsule contains a combination of Indacaterol (110 mcg) and Glycopyrrolate (50 mcg), formulated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Indacaterol is a long-acting beta2-adrenergic agonist (LABA) that provides sustained bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as breathlessness. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) that inhibits the action of acetylcholine on airway smooth muscle, leading to bronchodilation and decreased mucus secretion. The combination of these two agents offers complementary mechanisms of action, enhancing bronchodilatory effects and improving lung function more effectively than either component alone. Loftair Capsule is administered orally and is intended for once-daily use to maintain symptom control and reduce exacerbations in patients with moderate to severe COPD. It is contraindicated in patients with hypersensitivity to any of its components and should be used with caution in individuals with cardiovascular disorders, narrow-angle glaucoma, or urinary retention. Common adverse effects may include dry mouth, headache, and cough. Loftair Capsule should be used under medical supervision, with regular monitoring of respiratory status and potential side effects to optimize treatment outcomes.